Methods: A total of 123 patients with previously untreated stage IIIB/IV nonsquamous NSCLC without EGFR and/or ALK receptor tyrosine kinase gene (ALK) aberrations were randomized 1:1 to four cycles of PC with or without pembrolizumab, 200 mg every 3 weeks. Pembrolizumab treatment continued for 2 years; maintenance pemetrexed was permitted in both groups. Eligible patients in the PC-alone group with radiologic progression could cross over to pembrolizumab monotherapy. p Values are nominal (one-sided p < 0.025).
Results: As of December 1, 2017, the median follow-up time was 23.9 months. The ORR was 56.7% with pembrolizumab plus PC versus 30.2% with PC alone (estimated difference 26.4% [95% CI: 8.9%-42.4%, p ¼ 0.0016]). PFS was significantly improved with pembrolizumab plus PC versus PC alone (HR ¼ 0.53, 95% CI: 0.33-0.86, p ¼ 0.0049). A total of 41 patients in the PC-alone group received subsequent anti-programmed death 1/anti-programmed death ligand 1 therapy. The HR for OS was 0.56 (95% CI: 0.32-0.95, p ¼ 0.0151). Forty-one percent of patients in the pembrolizumab plus PC group and 27% in the PC-alone group had grade 3 to 5 treatment-related adverse events.
Conclusions: The significant improvements in PFS and ORR with pembrolizumab plus PC versus PC alone observed in the primary analysis were maintained, and the HR for OS with a 24-month median follow-up was 0.56, favoring pembrolizumab plus PC.
Introduction
Platinum-doublet chemotherapy has been the standard of care for first-line treatment of patients with advanced NSCLC without targetable genetic aberrations. 1 Monotherapy with pembrolizumab, an antiprogrammed death 1 (PD-1) monoclonal antibody, has demonstrated a benefit in both progression-free survival (PFS) and overall survival (OS) compared with platinum-based chemotherapy as first-line therapy for patients with advanced NSCLC with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of 50% or higher. 2 An OS benefit was also demonstrated with pembrolizumab versus with docetaxel in previously treated patients with advanced NSCLC with a PD-L1 TPS of 1% or higher. 3 Because chemotherapy mediates immunologic effects, 4 combining chemotherapy with anti-PD-1 immunotherapy may have a synergistic antitumor effect.
We previously published results from the primary analysis of cohort G of the multicohort phase 1/2 KEYNOTE-021 study (ClinicalTrials.gov, NCT02039674), which was an open-label, randomized phase 2 trial that evaluated pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone in patients with previously untreated advanced nonsquamous NSCLC. 5 With a minimum 6-month follow-up (median 10.6 months), patients in the pembrolizumab plus PC group had significant improvements in both objective response rate (ORR) 
Methods
The full eligibility criteria and other aspects of the study design and protocol (MK-3475-021-03) have been described previously. 5 In brief, to be eligible for cohort G of KEYNOTE-021, patients were required to have previously untreated stage IIIB or IV nonsquamous NSCLC without activating epidermal growth factor receptor (EGFR) mutations or ALK receptor tyrosine kinase gene (ALK) translocations, an Eastern Cooperative Oncology Group performance status of 0 or 1, no untreated brain metastases, and no interstitial lung disease or pneumonitis requiring systemic steroids. All patients were required to provide a tumor sample for assessment of tumor PD-L1 expression. Patients were stratified by PD-L1 TPS (<1% or 1%) and were randomized to receive PC (pemetrexed, 500 mg/m 2 , plus carboplatin, area under the concentration time curve [AUC] 5 mg/mL/min every 3 weeks for four cycles), alone or with pembrolizumab, 200 mg every 3 weeks for 2 years. Pemetrexed, 500 mg/m 2 every 3 weeks, was permitted as maintenance therapy and continued in the absence of disease progression or unacceptable toxicity. Patients in the PC-alone group could cross over to receive pembrolizumab monotherapy at the time of disease progression if they met eligibility criteria.
The primary end point was ORR, and PFS was the key secondary end point; both were evaluated by blinded independent central review. OS was an additional secondary end point. The planned enrollment (in the primary analysis) was 108 patients. The primary analysis (one-sided alpha ¼ 0.025) was controlled by a fixedsequence, closed-testing procedure stepping down from ORR to PFS. Because no alpha was assigned for this analysis, all reported p values are descriptive (one-sided p < 0.025).
Results
Overall, 123 patients were randomized (60 received pembrolizumab plus PC and 63 received PC alone). The baseline demographic and clinical characteristics have been previously reported. 5 One patient in each treatment group did not initiate treatment. At the current data cutoff (December 1, 2017), median follow-up across both treatment groups was 23.9 months (range 0.8-35.1 months). The median duration of randomized treatment was 10.1 months (range 0-29.0 months) in patients treated with pembrolizumab plus PC and 4.9 months (range 0-31.0 months) for patients treated with PC alone. Of the 59 patients treated with pembrolizumab plus PC, five (8.5%) were continuing treatment as of the data cutoff and 11 (18.6%) had completed treatment; 43 (72.9%) discontinued treatment (26 because of progression). Of the 62 patients treated with PC, six (9.7%) were continuing treatment and two (3.2%) had completed treatment; 54 (87.1%) had discontinued treatment (38 because of disease progression). Of the 56 patients in the PC-alone group who had discontinued or completed treatment, 26 (46.4%) crossed over to pembrolizumab during the study and 15 additional patients (26.8%) received anti-PD-1/PD-L1 therapy outside of crossover. Patients in the pembrolizumab plus PC group received a median of 14 cycles of pembrolizumab (range 1-41). In all, 52 patients in the pembrolizumab plus PC group (88.1%) and 44 in the PC-alone group (71.0%) received four cycles of carboplatin. All treated patients in both treatment groups received at least one cycle of pemetrexed; 50 patients in the pembrolizumab plus PC group (84.8%) and 42 in the PC-alone group (67.7%) received more than the initial four planned cycles of pemetrexed induction (i.e., they received maintenance pemetrexed). The median number of cycles of pemetrexed was 12 in the pembrolizumab plus PC group and 8 in the PC-alone group.
When compared with results from the prespecified primary analysis, 5 two additional confirmed responses were identified: one in the pembrolizumab plus PC group and one in the PC-alone group. The ORR was 56.7% with pembrolizumab plus PC and 30.2% with PC alone, with a between-group difference in ORR of 26.4% (95% CI: 8.9%-42.4%, nominal p ¼ 0.0016). With regard to responses observed, two patients in the pembrolizumab plus PC group and one patient in the PC alone group experienced a complete response that had evolved from a partial response at the primary analysis. As of this updated analysis, disease progression or death had occurred in 28 of 60 patients in the pembrolizumab plus PC group (47%) and 43 of 63 patients in the PC alone-group (68%). The HR for PFS was 0.53 (95% CI: 0.33-0.86, nominal p ¼ 0.0049), with a median PFS of 24.0 months in patients in the pembrolizumab plus PC group and 9.3 months for patients in the PC-alone group (Fig. 1A) .
At the time of analysis, 22 of 60 patients in the pembrolizumab plus PC group (37%) and 35 of 63 patients in the PC-alone group (56%) had died. Of the 35 deceased patients in the PC-alone group, 26 (74%) had received second-line immunotherapy. This represents an additional 30 deaths since the initial report (nine in the pembrolizumab plus PC group versus 21 in the PC-alone group). 5 The HR for OS was 0.56 (95% CI: 0.32-0.95, nominal p ¼ 0.0151). The median OS was NR in the pembrolizumab plus PC group (95% CI: 24.5 months-NR) and 21.1 months (95% CI: 14.9 months-NR months) in the PC-alone group (Fig. 1B) .
There were no new safety trends observed since the initial report. As of the current analysis, 55 of 59 patients in the pembrolizumab plus PC group (93.2%) and 57 of 62 patients in the PC-alone group (91.9%) experienced treatment-related adverse events (AEs) ( Table 1 ). Ten patients in the pembrolizumab plus PC group (16.9%) and eight in the PC-alone group (12.9%) experienced treatment-related AEs that led to discontinuation of any component of study medication. Grade 3 to 5 treatment-related AEs occurred in 24 patients (40.7%) and 17 patients (27.4%) in the pembrolizumab plus PC group and PC-alone group, respectively. Treatment-related fatal AEs occurred in one patient in the pembrolizumab plus PC group (1.7% [sepsis]) and two patients in the PC group (3.2% [pancytopenia and sepsis]), with no additional deaths occurring since the initial analysis. AEs with a presumed immunologic mechanism of action (regardless of attribution to study treatment or immune relatedness by the investigator) occurred in 17 patients in the pembrolizumab plus PC group (28.8%) and seven patients in the PC-alone group (11.3%).
Discussion
In this updated analysis, the HR for OS with pembrolizumab plus PC versus with PC alone after a median 23.9-month follow-up was 0.56 (95% CI: 0.32-0.95; nominal p ¼ 0.0151) compared with an HR of 0.90 in the primary analysis (a median 10.6-month follow-up). 5 The HR for OS favoring the pembrolizumab plus PC group occurred despite a high effective rate of crossover to anti-PD-1/PD-L1 therapy in the PC-alone group and despite the OS in the PC-alone group exceeding that for historical controls. 7 The statistically significant and clinically meaningful improvements in ORR and PFS observed in prior analyses of KEYNOTE-021 cohort G were maintained in this updated analysis. At the time of the current data cutoff, the median PFS in the pembrolizumab plus PC group was 24.0 months. As with OS, the median PFS in the PC-alone arm (9.3 months) was also longer than that previously reported with pemetrexed-platinum in patients with NSCLC. 2, 7 The relatively long OS and PFS in the PC-alone arm may have been due, at least in part, to the eligibility criteria excluding patients with poor prognosis (e.g., untreated brain metastases).
The findings from this phase 2 study have subsequently been confirmed by results from the phase 3 KEYNOTE-189 study, in which pembrolizumab plus pemetrexed-platinum reduced the risk of death by more than half compared with placebo plus pemetrexed-platinum (OS HR ¼ 0.49, 95% CI: 0.38-0.64, p < 0.001) in patients with previously untreated metastatic nonsquamous NSCLC without sensitizing EGFR mutations or ALK translocations. 8 Notably, the OS benefit observed with the combination of pembrolizumab plus pemetrexed and platinum in KEYNOTE-189 occurred regardless of tumor PD-L1 expression, with similar HRs across all PD-L1 TPS subgroups (for TPS 50%: HR ¼ 0.42, 95% CI: 0.26-0.68; for TPS 1%-49%: HR ¼ 0.55, 95% CI: 0.34-0.90; and for TPS <1%: HR ¼ 0.59, 95% CI: 0.38-0.92). Likewise, KEYNOTE-189 confirmed superior PFS with pembrolizumab plus pemetrexed-platinum versus placebo plus pemetrexed-platinum, with an HR for PFS (HR ¼ 0.52, 95% CI: 0.43-0.64, p < 0.001) similar to that shown in this long-term analysis from KEYNOTE-021 cohort G. 8 In addition to the noteworthy efficacy findings with long-term follow-up in KEYNOTE-021 cohort G, the combination of pembrolizumab plus PC continued to show a manageable safety profile. In comparison with pembrolizumab monotherapy in KEYNOTE-024, a higher percentage of patients treated with pembrolizumab plus PC in this long-term analysis of KEYNOTE-021 cohort G experienced treatment-related AEs leading to discontinuation (7% versus 17%, respectively) and grade 3 to 5 treatment-related AEs (27% versus 41%, respectively). 2 However, additional toxicity with a combination treatment regimen containing platinum chemotherapy is not unexpected. Importantly, in the larger, double-blind, placebo-controlled, phase 3 study KEYNOTE-189, there was no evidence that AEs commonly associated with pemetrexed-platinum were exacerbated with the addition of pembrolizumab; the exception may be renal toxicity, which was manageable overall. 8 Moreover, the increased toxicity with pembrolizumab plus PC versus with pembrolizumab alone may be offset by improved efficacy outcomes. Although cross-trial comparisons should be made with caution, it is notable that the OS HR of 0.42 for patients with a PD-L1 TPS of 50% or higher in KEYNOTE-189 8 compares favorably with the OS HR of 0.58 (95% CI: 0.41-0.83) for the nonsquamous subgroup of KEYNOTE-024. 9 Notably, outcomes for patients with a TPS of 50% or higher and any histologic type treated with pembrolizumab versus with platinum-based chemotherapy in the phase 3 KEYNOTE-042 study were similar to those in KEYNOTE-024 (OS HR ¼ 0.69, 95% CI: 0.56-0.85). 10 Pembrolizumab plus PC, which has been granted accelerated U.S. Food and Drug Administration approval, represents an effective and tolerable treatment option for use as initial therapy for eligible patients with advanced nonsquamous NSCLC.
